Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342023 | 1.00 | GABRR1 (0.35) | GABRR1HDAC6AAK1MEN1GAA | |
| SCHEMBL18634785 | 0.82 | HDAC6 (0.33) | HDAC6 | |
| SCHEMBL5724032 | 0.80 | HDAC6 (0.34) | HDAC6MEN1GAAKMT2A | |
| SCHEMBL20247628 | 0.77 | HDAC6 (0.33) | HDAC6 | |
| SCHEMBL343494 | 0.77 | CTSS (0.38) | HDAC6 | |
| SCHEMBL343493 | 0.77 | CTSS (0.38) | HDAC6 | |
| SCHEMBL3901647 | 0.76 | HDAC6 (0.32) | HDAC6 | |
| SCHEMBL9188157 | 0.74 | MAOB (0.48) | — | |
| SCHEMBL9190936 | 0.74 | MAOB (0.48) | — | |
| SCHEMBL11251412 | 0.74 | EPOR (0.39) | MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835422-B2 | Substituted imidazoheterocycle derivatives | CARA THERAPEUTICS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120015930-A1 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CARA THERAPEUTICS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015930-A1 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CNR1, CNR2, HRH1 | GABRR1 517/4885HDAC6 1246/4885AAK1 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.